{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:30:08Z","timestamp":1792189808152,"version":"4.4.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024396","name":"Healthcare Quality Improvement Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024396","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intermune"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHSE-NIHR"},{"DOI":"10.13039\/501100000574","name":"British Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000574","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Growing evidence suggests that biological sex influences the incidence, presentation, diagnosis and outcomes of many lung diseases. Understanding these differences is the first step towards precision medicine to improve patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, idiopathic pulmonary fibrosis (IPF) patients enrolled in a national (UK), multicentre registry were categorised by sex and analysed for differences in demographics, pulmonary function tests, high resolution CT radiological pattern, eligibility\/uptake of antifibrotics and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 7177 cases, 77.8% (n=5587) were male, median age 75 years (IQR 69.5\u201380.5) for both sexes (p=0.83). Males were more likely to have a history of smoking (males 72.9% vs females 60.5%, p&lt;0.001) and lower baseline median forced vital capacity (FVC) % predicted (males 76.4%, IQR 66.2\u201386.7 vs females 78.8%, IQR 68.6\u201389.1, p&lt;0.001). Diabetes (males 22.8% vs females 15.1%) and cardiovascular disease (males 58.9% vs females 47.8%) were statistically more common in males (p&lt;0.001), while gastro-oesophageal reflux disease (males 20% vs females 24.6%) and major depressive illness (males 0.8% vs females 2.5%) were more common in females (p&lt;0.001). Significantly, more females experienced symptoms for &gt;24 months prior to first clinic appointment (females 40.1% vs males 36.6%, p=0.03). While more males in the cohort met eligibility criteria for antifibrotics at baseline (pirfenidone FVC 50%\u201380% males 54.7% vs females 47.6%, nintedanib FVC 50%\u201380% males 47.0% vs females 41.5%, p&lt;0.001), a larger proportion chose not to commence antifibrotic treatment (males 47.0% vs females 29.6%, p&lt;0.001). Female sex was associated with longer survival; for females, the 75% Kaplan-Meier survival quartile is 7.6 years (95%\u2009CI 5.51 to 9.68 years) versus 4.3 years (95%\u2009CI 3.82 to 4.78) for males (p&lt;0.001). Male sex (HR 1.76 (95% CI 1.22 to 2.54), p=0.002), higher age (HR 1.042 (95% CI 1.02 to 1.06),\u2009p&lt;0.001), lower baseline FVC % predicted (HR 0.98 (95% CI 0.97 to 0.98),\u2009p&lt;0.001) and coexistent lung cancer (HR 9.3 (95% CI 2.86 to 30.24),\u2009p&lt;0.001) were all independently associated with worse survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first UK study to use national registry data to systematically evaluate IPF disease characteristics stratifying by biological sex and highlights distinct characteristics between groups. Future clinical trials should explicitly explore sex-specific targeted interventions and analyses to optimise future IPF patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003301","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:25:24Z","timestamp":1758792324000},"page":"e003301","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in disease characteristics and outcomes as determined by biological sex in a large UK idiopathic pulmonary fibrosis population: analysis from the British Thoracic Society, Interstitial Lung Disease registry data"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3758-4164","authenticated-orcid":false,"given":"Sarah","family":"Mulholland","sequence":"first","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"},{"name":"Academic Respiratory Unit, University of Bristol Faculty of Health Sciences, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-0739","authenticated-orcid":false,"given":"Giles","family":"Dixon","sequence":"additional","affiliation":[{"name":"Academic Respiratory Unit, University of Bristol Faculty of Health Sciences, Bristol, UK"},{"name":"Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wells","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-2094","authenticated-orcid":false,"given":"Sam","family":"Harding","sequence":"additional","affiliation":[{"name":"Research and Innovation, NHS North Bristol NHS Trust, Bristol, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[{"name":"Mathematics and Statistics Research Group, University of the West of England, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0468-3537","authenticated-orcid":false,"given":"Anne-Marie","family":"Russell","sequence":"additional","affiliation":[{"name":"School of Medicine and Health, College of Medical and Dental Sciences (MDS) University of Birmingham, Birmingham, West Midlands, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7349","authenticated-orcid":false,"given":"Shaney L","family":"Barratt","sequence":"additional","affiliation":[{"name":"Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026010701512686000_12.1.e003301.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-163OC"},{"key":"2026010701512686000_12.1.e003301.2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.rmed.2009.11.019","article-title":"Gender influences Health-Related Quality of Life in IPF","volume":"104","author":"Han","year":"2010","journal-title":"Respir Med"},{"key":"2026010701512686000_12.1.e003301.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0994-4","article-title":"Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden","volume":"19","author":"Kalafatis","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026010701512686000_12.1.e003301.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.02.009"},{"key":"2026010701512686000_12.1.e003301.5","doi-asserted-by":"crossref","unstructured":"Sese L , Nunes H , Cottin V , et al . Gender differences in idiopathic pulmonary fibrosis: are men and women equal or not? ERS International Congress 2020 abstracts; September 7, 2020:713698. doi:10.1183\/13993003.congress-2020.764","DOI":"10.1183\/13993003.congress-2020.764"},{"key":"2026010701512686000_12.1.e003301.6","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00122.2011"},{"key":"2026010701512686000_12.1.e003301.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0562OC"},{"key":"2026010701512686000_12.1.e003301.8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.rmed.2019.08.006","article-title":"Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis","volume":"156","author":"Vancheri","year":"2019","journal-title":"Respir Med"},{"key":"2026010701512686000_12.1.e003301.9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1513\/AnnalsATS.202009-1122OC","article-title":"Treatment Initiation in Patients with Interstitial Lung Disease in Canada","volume":"18","author":"Assayag","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026010701512686000_12.1.e003301.10","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00187-2020","article-title":"Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019","volume":"7","author":"Spencer","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026010701512686000_12.1.e003301.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2024-002773","article-title":"Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry","volume":"12","author":"Fahim","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"2026010701512686000_12.1.e003301.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2026010701512686000_12.1.e003301.13","unstructured":"TA282 NICE-TAG . Pirfenidone for treating idiopathic pulmonary fibrosis, 2013. Available: https:\/\/www.nice.org.uk\/Guidance\/TA2822013 [Accessed 4 Mar 2025]."},{"key":"2026010701512686000_12.1.e003301.14","unstructured":"TA379 NICE-TAG . Nintedanib for treating Idiopathic Pulmonary Fibrosis, 2016. Available: https:\/\/www.nice.org.uk\/guidance\/ta3792016 [Accessed 3 Mar 2025]."},{"key":"2026010701512686000_12.1.e003301.15","unstructured":"TA864 NICE-TAG . Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted, 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta8642023 [Accessed 28 Feb 2025]."},{"key":"2026010701512686000_12.1.e003301.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00004"},{"key":"2026010701512686000_12.1.e003301.17","unstructured":"QS79 NICE-Quality Standard . Idiopathic pulmonary fibrosis in adults, 2015. Available: https:\/\/www.nice.org.uk\/guidance\/qs792015 [Accessed 3 Mar 2025]."},{"key":"2026010701512686000_12.1.e003301.18","unstructured":"CG163 NICE-Clinical Guideline . National Institure for Health Care Excellence; Idiopathic Pulmonary Fibrosis in adults: diagnosis and management, 2013. Available: https:\/\/www.nice.org.uk\/guidance\/cg163 [Accessed 3 Mar 2025]."},{"key":"2026010701512686000_12.1.e003301.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-017-0560-x","article-title":"Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey","volume":"18","author":"Cosgrove","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2026010701512686000_12.1.e003301.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107612"},{"key":"2026010701512686000_12.1.e003301.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.03.012"},{"key":"2026010701512686000_12.1.e003301.22","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213968"},{"key":"2026010701512686000_12.1.e003301.23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-214569"},{"key":"2026010701512686000_12.1.e003301.24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chest.2023.02.027","article-title":"Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis","volume":"164","author":"Kaul","year":"2023","journal-title":"Chest"},{"key":"2026010701512686000_12.1.e003301.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2024.06.1913","article-title":"RACIAL AND GENDER DISPARITIES, AND IMPACT OF ANTIFIBROTIC THEPARY ON HOSPITAL OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS","volume":"166","author":"Ghimire","year":"2024","journal-title":"Chest"},{"key":"2026010701512686000_12.1.e003301.26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13092727","article-title":"Understanding Patterns of Adherence to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis: Insights from an Italian Prospective Cohort Study","volume":"13","author":"Iommi","year":"2024","journal-title":"J Clin Med"},{"key":"2026010701512686000_12.1.e003301.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001687","article-title":"Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study","volume":"11","author":"Romero Ortiz","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026010701512686000_12.1.e003301.28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000496735","article-title":"A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT","volume":"98","author":"Jouneau","year":"2019","journal-title":"Respiration"},{"key":"2026010701512686000_12.1.e003301.29","doi-asserted-by":"crossref","unstructured":"Tondo P , Scioscia G , De Pace CC , et al . n.d. Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction. Life 15:106. doi:10.3390\/life15010106","DOI":"10.3390\/life15010106"},{"key":"2026010701512686000_12.1.e003301.30","unstructured":"Ramsey D . Parliamentary Office of Science and Technology (POST). POSTbrief 56: Men\u2019s Health. UK Parliament, 2023. Available: https:\/\/researchbriefings.files.parliament.uk\/documents\/POST-PB-0056\/POST-PB-0056.pdf [Accessed 11 Mar 2025]."}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:52:46Z","timestamp":1767779566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjresp-2025-003301"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003301","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}